FDA Approves Eli Lilly's Omvoh as First-in-Class Treatment for Ulcerative Colitis
TL;DR Summary
The FDA has approved Eli Lilly's new drug, Omvoh, for the treatment of ulcerative colitis. Omvoh is an antibody that blocks IL-23p19, a molecule involved in sustaining the disease. Clinical trials showed significant improvement in symptoms for patients taking Omvoh compared to a placebo, with minimal side effects. The drug's list price is $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin, but patients with commercial insurance may pay as little as $5 per month for up to 30 months.
- FDA approves Eli Lilly ulcerative colitis treatment Omvoh - STAT STAT
- Lilly's bowel disease drug gets US FDA nod for treatment in adults Reuters
- FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis | Eli Lilly and Company Investors | Eli Lilly and Company
- Delayed FDA nod moves Lilly to crowded ulcerative colitis market FiercePharma
- FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis PR Newswire
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
48%
165 → 85 words
Want the full story? Read the original article
Read on STAT